MGMT and central nervous system cancer: Next, clinical data from glioma patients with concurrent MS were compared with data from control patients without MS and matched for tumor histology and the known prognostic markers IDH- and MGMT-status, age at diagnosis, and Karnofsky-Index (Supplementary Tables 3, 4).